Integrative Analysis of m6A RNA Methylation Regulators and the Tumor Immune Microenvironment in Non-Small-Cell Lung Cancer

Figure 8

Role of m6A modification patterns in IPS and anti-PD-1/L1 immunotherapy. (a) Wilcoxon test showed differences in PD-L1 expression between the two assessment subgroups. (b, c) Box plots and histograms showing prognostic analysis of survival in the high m6Ascore group or low m6Ascore group (0: alive; 1: dead). (d–i) Kaplan–Meier graphs depict differences in clinical relevance between the two assessment subgroups, including age and T and N stages. (j–m) Immunotherapy scoring for the low m6Ascore group and the high m6Ascore group (po: positive; neg: negative).

(a)

(b)

(c)

(d)

(e)

(f)

(g)

(h)

(i)

(j)

(k)

(l)

(m)